Your gate­way

to finance

and inno­va­tion

in Cen­tral Europe


Sev­enth Cen­tral Euro­pean Life Sci­ence Invest­ment Conference

Hotel Stary, Krakow, 2527 October2017

This year’s theme:
“Invest­ment and com­mer­cial­iza­tion: time for inter­na­tion­al­iza­tion and collaboration”


25 Octo­ber 2017
18.00 Reg­is­tra­tion open
18.00 Pre-​conference Drinks Recep­tion at the Hotel Stary
Spon­sored by Slater Heelis (UK)

26 Octo­ber 2017


08.15 Reg­is­tra­tion Open


Roland Kozlowski, LSBC (Poland)

9.15 Ses­sion: The big pic­ture in life sciences


Talk: Dig­i­tal Health — What’s in it for me?

Mar­tin Oxley, IORMA (Poland)


Talk: Invest­ment in Inno­va­tion – should strat­egy be bipartisan

Mark Tre­herne, For­mer Gov­ern­ment Advi­sor (UK)


Talk: Doing health­care busi­ness in Poland

Michael Dem­bin­ski, British Pol­ish Cham­ber of Com­merce (PL)

10.4511.30 Cof­fee & Networking
11.30 Ses­sion VC investment

Talk: Invest­ing in and run­ning high growth busi­nesses – per­sonal experiences

Maciek Drozdz, JNJ Ven­tures, (UK)


Panel: VC thoughts on the present

Mod­er­a­tor: Roland Kozlowski

Mateusz Kowalewski, Augere Ven­ture (Poland)

Woj­ciech Tworzyński, JPIF (Poland)

Peter Dudek, Wellign­ton Part­ners (Ger­many)
Maciek Drozdz, JNJ Ven­tures, (UK)

12.4514.00 Net­work­ing lunch

14.00 Ses­sion: Tech Trans­fer


Talk: Tech Trans­fer — Deal Struc­tures and Legal Perspectives

Simon Wall­work, Slater Heelis (UK)


Talk: Tech Transfer

Gabor Lamm, EMBLEM Tech­nol­ogy Trans­fer GmbH (Germany)


Panel: Tech Trans­fer: Lessons to learn from mature mar­kets
Mod­er­a­tor: Gabor Lamm
Krzysztof Jakubczak, nanoEmi (Poland)
Radosław Rudź, CIT­TRU (Poland)
Joern Erselius, Max Planck (Ger­many)
Ste­fan Ogrodzin­ski, Bioc­ity (UK)
Simon Wall­work, Slater Heelis (UK)


TEA & Networking


Arm Chair Dis­cus­sion: Deals in the CRO world
Jane Eis­ner, Quin­tiles (UK)

Per­sonal per­spec­tives and the CRO/​Pharma indus­try landscape


More Poland Limited

Talk: A dietary sup­ple­ment for the after effects of alco­hol intoxication

Katarzyna Koziak, War­saw Med­ical Uni­ver­sity (Poland)


Talk: Start­ing, financ­ing and deals

Pawel Bochniarz, Val­ueTech Seed (PL)

17.45 Con­fer­ence close for the day

Net­work­ing drinks, Con­fer­ence Din­ner, Live Music: Restau­rant Pod Roza

27 Octo­ber 2017

07.45 Busi­ness Break­fast: Intel­lec­tual Prop­erty Man­age­ment
Spon­sored by WTS Patent (Poland)
Case Study: Anna Grze­lak and Andrzej Witek, WTS (Poland)

09.00 Ses­sion: The Pol­ish Early Stage Pharma Scene
09.00 Talk: Mag­dalena Marciniak, Selvita (Poland)
09.30 Talk: Marcin Szu­mowski, Oncoarendi (Poland)
10.00 Talk: Mał­gorzata Mau­rer, Pol­pharma Bio­log­ics (Poland)

Cof­fee & Networking

11.00 Busi­ness Devel­op­ment and Alliance Management

Panel: Busi­ness Devel­op­ment, Deals and Internationalization

Mod­er­a­tor: Mark Treherne

Olga Krylova, Pfizer (UK)
Jarek Oleszczuk, Astra Zeneca (Poland)
Nico­las Beuzen, Oncoarendi (Poland)

Irina Staatz, Staatz Busi­ness Devel­op­ment (Germany)

Pawel Bochniarz, Val­ueTech Seed (PL)


Talk: George Rahim, UCB (Bel­gium)
Alliance Man­age­ment: Deliv­er­ing value from Life Sci­ence Partnering


Ses­sion: Com­pany Pre­sen­ta­tions
Quick break then cof­fee served in con­fer­ence hall
In part­ner­ship with Life Sci­ence Open Space

• Med­ical Sim­u­la­tion Tech­nolo­gies Sp. z o.o.

Win­ner “Life Sci­ence Open Space Competition”

• Mon­i­tor CR Sp. z o.o.
Run­ner up “Life Sci­ence Open Space Competition”

• Real Research Sp. z o.o.
• Cap­tor Ther­a­peu­tics Sp z o.o.


Con­fer­ence Close and summing-​up

Roland Kozlowski


Sev­enth Cen­tral Euro­pean Life Sci­ence Invest­ment Conference

Hotel Stary, Krakow, 2527 Octo­ber 2017

    • Early bird registration

until 8th Sep­tem­ber 2017

1200 PLN + 23% VAT

or €340 + 23% VAT

    • Stan­dard registration

from 9th Sep­tem­ber 2017

2000 PLN + 23% VAT

or €570 + 23% VAT

    • Accom­pa­ny­ing persons

If you would like to bring a friend do please con­tact us.

If there is suf­fi­cient inter­est we will develop an

agenda for accom­pa­ny­ing persons.

There will be a mod­est fee.

    • Extra din­ner guest

270zl + 23% VAT

77 + 23% VAT

By reg­is­ter­ing you acknowl­edge that you have read the dis­claimer and under­stood the can­cel­la­tion policy

Pay­ment by bank trans­fer in Euros to: PKO Bank Pol­ski in Krakow

94 1440 1127 0000 0000 1386 1129

Pay­ment by bank trans­fer in Pol­ish zloty to: PKO Bank Pol­ski in Krakow

68 1440 1127 0000 0000 1134 2701



Pow­ered by BreezingForms


        • Nicolas-Beuzen
          Nico­las Beuzen
        • Pawel-Bochniarz
          Paweł Bochniarz
        • Michael-Dembinski
          Michael Dem­bin­ski
        • Maciek-Drozdz
          Maciek Drozdz
        • Peter-Dudek
          Peter Dudek
        • JaneEisner
          Jane Eis­ner
        • Jorn-Erselius
          Jorn Erselius
        • Anna-Grzelak
          Anna Grze­lak
        • Krzysztof-Jakubczak
          Krzysztof Jakubczak
        • Roland-Kozlowski
          Roland Kozłowski
        • KatarzynaKoziak
          Katarzyna Koziak
        • MateuszKowalewski
          Mateusz Kowalewski
        • OlgaKrylova
          Olga Krylova
        • dr-Gabor-Lamm
          Gabor Lamm
        • MagdalenaMarciniak
          Mag­dalena Marciniak
        • Stefan-Ogrodzinski
          Ste­fan Ogrodzinski
        • Jaroslaw-Oleszczuk
          Jarosław Oleszczuk
        • Martin-Oxley
          Mar­tin Oxley
        • George-Rahim
          George Rahim
        • Radoslaw-Rudz
          Radosław Rudź
        • Marcin-Szumowski
          Marcin Szu­mowski
        • IrinaStaatzGranzer
          Irina Staatz Granzer
        • Mark-Treherne
          Mark Tre­herne
        • Wojciech-Tworzynski
          Woj­ciech Tworzyński
        • Simon-Wallwork
          Simon Wall­work


Nico­las Beuzen

Busi­ness Devel­op­ment Direc­tor. Nico­las has over 15 years’ expe­ri­ence work­ing for var­i­ous bio­phar­ma­ceu­ti­cal com­pa­nies in France, India and Poland, from large and mid-​size pharma, to start-​ups. In his dif­fer­ent roles includ­ing chief sci­en­tific offi­cer and busi­ness devel­op­ment direc­tor, he has gained broad and applied knowl­edge in the devel­op­ment of new chem­i­cal enti­ties (NCEs) and bio­log­ics for neu­rode­gen­er­a­tive dis­eases, oncol­ogy and rare dis­eases. Work­ing with high per­for­mance, inter­na­tional R&D teams, he obtained expe­ri­ence in eval­u­a­tion, nego­ti­a­tion and man­age­ment of strate­gic alliances and part­ner­ships. Nico­las is co-​inventor on 2 patents. He holds a PhD in mol­e­c­u­lar biol­ogy and genomics from the Uni­ver­sity of Glas­gow and a mas­ter in man­age­ment and admin­is­tra­tion from the Uni­ver­sité Lyon III in France.


Paweł Bochniarz

Pawel is a ser­ial entre­pre­neur, advi­sor, men­tor, and expert in com­mer­cial­iza­tion of new technologies.

Pawel’s cur­rent role is Chair­man of MIT Enter­prise Forum Poland. MIT Enter­prise Forum (MITEF) is a global orga­ni­za­tion of ded­i­cated pro­fes­sion­als with local chap­ters, affil­i­ated with the Mass­a­chu­setts Insti­tute of Tech­nol­ogy (MIT). MIT EF helps early-​stage tech­nol­ogy entre­pre­neurs suc­ceed faster through rel­e­vant and prac­ti­cal pro­gram­ming and con­tent to help them tackle real-​world challenges.

Pre­vi­ously Pawel worked i.a. as the Inno­va­tion Advi­sory Direc­tor at PwC. In this capac­ity Pawel co-​operated with pub­lic research insti­tu­tions and tech­nol­ogy star­tups in Poland to help com­mer­cial­ize their IP. In the years 20082010 Pawel also was a Mem­ber of the Advi­sory Board of the Prime Min­is­ter of Poland, co-​ordinating prepa­ra­tions of the first Report on the National Intel­lec­tual Cap­i­tal of Poland.

Pawel is also a Part­ner at Val­ueTech – a seed-​stage ven­ture cap­i­tal fund and sits on invest­ment boards of two uni­ver­sity gap funds in Poland.

Pawel is a co-​founder of Coali­tion For Pol­ish Inno­va­tions – a public-​private part­ner­ship estab­lished in 2015 to develop the Pol­ish inno­va­tion Ecosystem

Pawel is an alum­nus of Eco­nom­ics stud­ies at the Uni­ver­sity of War­saw. He also com­pleted the Advanced Man­age­ment Pro­gram at IESE Busi­ness School. Expert and Adviser expe­ri­enced within the field of star­tups cre­ation and acceleration.


Michael Dem­bin­ski

Michael Dem­bin­ski was born in Lon­don in 1957. Edu­cated at War­wick Uni­ver­sity and The City Uni­ver­sity, he worked for 16 years at the Con­fed­er­a­tion of British Indus­try, nine years as man­ag­ing edi­tor of its monthly mag­a­zine, CBI News. In 1997, Michael moved to Poland with his young fam­ily to take up the posi­tion of direc­tor of com­mu­ni­ca­tions at Pol­ska Telewizja Kablowa (now UPC Pol­ska). In 1999, Michael became man­ag­ing direc­tor of clas­si­fied adver­tis­ing pub­lisher Trader​.com Pol­ska (now a part of Agora S.A.). Since 2002, he has been work­ing with the British Pol­ish Cham­ber of Com­merce, where he is chief advisor.‎


Maciek Drozdz

Prin­ci­pal, Ven­ture Investments.

Maciek Drozdz is a Prin­ci­pal of Ven­ture Invest­ments for John­son and John­son Devel­op­ment Cor­po­ra­tion (JJDC) and joined in 2017. Maciek is based in Lon­don at the John­son and John­son Inno­va­tion Centre.

Maciek has spent 10 years work­ing in the Ven­ture Cap­i­tal and biotech indus­try. Most recently he served as a CEO of Antag­o­nis Bio­ther­a­peu­tics, an immuno-​oncology com­pany in Graz, Aus­tria. Pre­vi­ously he was invest­ment man­ager at Entre­pre­neurs Fund LLP, invest­ment direc­tor at MCI Bioven­tures and an ana­lyst at Atlas Ven­ture. Maciek has served on a num­ber of boards of pri­vate and pub­lic com­pa­nies across sev­eral countries.

Maciek received his Master’s Degree in mol­e­c­u­lar biol­ogy from the Adam Mick­iewicz Uni­ver­sity in Poz­nan, Poland fol­lowed by a Doc­tor­ate at the Uni­ver­sity of Hei­del­berg in Ger­many. He has also worked as a Post­doc at the Friedrich Miescher Insti­tute in Basel, Switzer­land. Maciek holds an MBA degree from the Said Busi­ness School in Oxford. He lec­tured a course in “Inno­va­tion in Biotech­nol­ogy” at Adam Mick­iewicz University.


Peter Dudek

Peter joined Welling­ton Part­ners in Feb­ru­ary 2016 as a Prin­ci­pal. Prior to join­ing Welling­ton, Peter was an Invest­ment Asso­ciate at Entre­pre­neurs Fund, a London-​based pan-​European ven­ture fund with more than $200m of assets under man­age­ment. Peter served as a Board Observer on Vasopharm and Opti­nose, and sup­ported mul­ti­ple trans­ac­tions across the life sci­ences port­fo­lio includ­ing invest­ments in Vasopharm, Opti­nose, Cytoo, Sequana Med­ical and Prosonix, as well as Prosonix’s sale to Circassia.

Before EF, Peter con­sulted for a num­ber of Euro­pean venture-​backed biotech­nol­ogy star­tups and was an interned Ana­lyst at Novar­tis Ven­ture Funds. In his prior life as a sci­en­tist, Peter worked in the field of ncR­NAs and chro­matin remod­el­ling as a Research Fel­low at the Uni­ver­sity of Oxford (Queen’s), obtained his PhD from the Uni­ver­sity of Geneva in oncol­ogy, and a BSc (Hons) in immunol­ogy from the Uni­ver­sity of British Colum­bia. He also con­ducted research on the Hepati­tis C virus at the BC Cen­tre for Dis­ease Control.


Jane Eis­ner

Jane Eis­ner heads Euro­pean Sales and Account Man­age­ment for Quin­tiles­IMS, where she is respon­si­ble for the growth and deliv­ery of the R&D busi­ness port­fo­lio in Europe, includ­ing global strate­gic partnerships.

With more than 20 years with Quin­tiles, Jane has held a vari­ety of lead­er­ship posi­tions across sales, account man­age­ment and study deliv­ery. Build­ing on her strong per­for­mance track record, her pas­sion for cus­tomer ser­vice is a key attribute as she devel­ops part­ner­ing solu­tions for her cus­tomers. One of Jane’s proud­est achieve­ments cre­at­ing Quin­tiles’ “Global Access to Patients” group, which deliv­ers patient out­reach and engage­ment pro­grams plus an inves­ti­ga­tor part­ner pro­gram that is now core to R&D Solu­tions study delivery.

Jane holds a Bach­e­lor of Sci­ence degree in phar­macy from the Uni­ver­sity of Bath UK.


Jörn Erselius

Jörn Erselius is Man­ag­ing Direc­tor of Max Planck Inno­va­tion (MI), the tech­nol­ogy trans­fer agency of the Max Planck Soci­ety (MPG), the largest Ger­man basic research orga­ni­za­tion. He joined MI in 1991 as Patent– and Licens­ing Man­ager and was respon­si­ble for advis­ing inven­tors and com­mer­cial­iz­ing tech­nol­ogy in the life sci­ence field. Later he took over respon­si­bil­ity for the patent and licens­ing depart­ment of MI. He nego­ti­ated numer­ous license agree­ments and con­sulted many spin offs from Max Planck Insti­tutes, such as Evotec or Alnylam.

Jörn Erselius stud­ied Biol­ogy at the Uni­ver­sity of Hei­del­berg and joined for his PHD stud­ies the Depart­ment of Prof. Peter Gruss at the Max Planck Insti­tute for Bio­phys­i­cal Chem­istry in Göttingen.

In 2004 he received his “Mas­ter of Busi­ness Admin­is­tra­tion (MBA)”, main focus: Man­age­ment, from the Uni­ver­sity of Applied Sci­ences in Deggen­dorf. He wrote his mas­ter the­sis on the topic “Patent­ing biotech­no­log­i­cal inven­tions in Europe and the US”.

Since 2011 he is “Reg­is­tered Tech­nol­ogy Trans­fer Pro­fes­sional, RTTP” (granted by ATTP, the Alliance of Tech­nol­ogy Trans­fer Professionals).

Jörn Erselius served for four years as Vice Pres­i­dent of ASTP (Asso­ci­a­tion of Euro­pean Sci­ence & Tech­nol­ogy Trans­fer Pro­fes­sion­als) and rep­re­sents Max Planck Inno­va­tion and the Max Planck Soci­ety in boards of Max Planck spin offs and as expert in sev­eral national and inter­na­tional com­mit­tees (BMBF, BMWi, Euro­pean Com­mis­sion, OECD).


Anna Grze­lak

Anna is a part­ner at WTS Patent Attor­neys and a Pol­ish and Euro­pean patent attor­ney spe­cial­is­ing in the solu­tions in the areas of biotech­nol­ogy, phar­macy, human and vet­eri­nary med­i­cine and patent searches. She holds a PhD in biology.

Anna is a mem­ber of the Pol­ish Cham­ber of Patent Attor­neys. She speaks native Pol­ish, flu­ent Eng­lish and has a basic under­stand­ing of Russ­ian. Anna grad­u­ated with MSc from the Fac­ulty of Biol­ogy of the Uni­ver­sity of War­saw with a spe­cial­i­sa­tion in Micro­bi­ol­ogy. She per­formed her PhD the­sis research at the Insti­tute of Genet­ics of the Uni­ver­sity of War­saw and obtained her Hon­ours PhD in biol­ogy with a spe­cial­i­sa­tion in genetics.

Anna obtained a post-​graduate diploma in Indus­trial Prop­erty Law at the Fac­ulty of Law and Admin­is­tra­tion of the Uni­ver­sity of War­saw. She also under­went the attor­ney course offered by the Pol­ish Cham­ber of Patent Attor­neys. She is a Pol­ish patent attor­ney, and is also licensed to rep­re­sent clients before the Office for the Har­mon­i­sa­tion of the Inter­nal Mar­ket (OHIM) in mat­ters relat­ing to com­mu­nity trade­marks and indus­trial designs.

Prior to join­ing WTS Patent Attor­neys, she spent seven years in another large patent agency in War­saw. As a Pol­ish patent attor­ney and part­ner at WTS Patent Attor­neys she ser­vices lead­ing global biotech­no­log­i­cal, phar­ma­ceu­ti­cal, vet­eri­nary and chem­i­cal com­pa­nies, in mat­ters relat­ing to the pro­tec­tion of inven­tions. She works in War­saw office.


Krzysztof Jakubczak

Krzysztof Jakubczak, PhD, is a grad­u­ate from the Insti­tute of Opto­elec­tron­ics of the Mil­i­tary Uni­ver­sity of Tech­nol­ogy in War­saw (MSc) and Czech Tech­ni­cal Uni­ver­sity in Prague (PhD). Addi­tion­ally, has built his pro­fes­sional skills at Stan­ford Uni­ver­sity (USA), Lab­o­ra­toire d’Optique Appliquée – LOA (France), Korean Advanced Insti­tute of Sci­ence and Tech­nol­ogy – KAIST (South Korea), Desy Syn­chro­tron in Ham­burg (Ger­many), Uni­ver­si­dad de Sala­manca (Spain) and many others.

Krzysztof’s exper­tise cov­ers: med­ical devices, lasers, optics, infrared tech­nol­ogy, light detec­tion, sec­ondary sources, lith­o­g­ra­phy, vac­uum sys­tems, spec­tro­scopic meth­ods, and defense. Krzysztof is expe­ri­enced R&D engi­neer and man­ager in the opto­elec­tron­ics domain. He worked as a Deputy Project Man­ager at new R&D HiLASE Cen­ter in Czech Repub­lic on inno­v­a­tive laser tech­nolo­gies for indus­try. He was respon­si­ble there for busi­ness devel­op­ment and man­age­ment of a research pro­gram. Krzysztof’s com­mer­cial expe­ri­ence cov­ers run­ning engi­neer­ing depart­ment at a med-​tech com­pany, build­ing a com­pany from a startup phase to the fully oper­a­tion pro­duc­tion facil­ity, build­ing and man­ag­ing a num­ber of star­tups devel­op­ing var­i­ous new tech­nolo­gies (med-​tech, mate­r­ial sci­ences, opto­elec­tron­ics). He is also an active advi­sory con­sul­tant in com­mer­cial­iza­tion and tech-​transfer fields. He worked as an Oper­a­tions Direc­tor for the National Cen­ter for Research and Devel­op­ment where he with his team was respon­si­ble for eval­u­a­tion and com­mer­cial­iza­tion activ­i­ties in Life Sci­ences field (pharma, med-​tech, agro). Krzysztof coop­er­ates with Laser­Lab Europe, MIT Enter­prise Forum Poland, Pol­ish Stan­dard­iza­tion Com­mit­tee, investors and tech­no­log­i­cal innovators.

Roland Kozłowski

Roland Kozłowski

Roland received a first class hon¬ours degree from the Uni¬ver¬sity of Bath and a PhD from the Uni­ver­sity of Cam­bridge. He is a ser­ial bioen­tre­pre­neur, investor and men­tor who has worked in the indus­try for over twenty five years. Roland was Chief Exec­u­tive Offi­cer of Lec­tus Ther­a­peu­tics and Sense Pro­teomic Lim­ited two ven­ture cap­i­tal backed com­pa­nies which he founded, built and sold. Dur­ing his career Roland has lead or played a key role in a many trans­ac­tions includ­ing com­pany financ­ing, sale, pur­chase, financ­ing and in and out-​licensing with a cumu­la­tive value of over $200m. Ear­lier in his career Roland ran Research Groups at the Uni­ver­sity of Oxford and Univer¬sity of Bris­tol where he pub­lished and patented in the life sci­ence field. He has been a Vis­it­ing Indus­trial Pro­fes­sor, served on, or advised the boards of sev­eral Euro­pean com­pa­nies and orga­ni­za­tions includ­ing the Bio-​Industry Asso­ci­a­tion in the UK. Presently he is Pres­i­dent and owner of Life Sci­ence Biznes Con­sult­ing which spe­cial­izes in com­mer­cial­iz­ing tech­nol­ogy from emerg­ing economies par­tic­u­larly in Poland. He has acted as an advi­sor to the National Cen­tre of Research & Devel­op­ment in Poland and the Pol­ish Devel­op­ment Agency. He is a founder and lim­ited part­ner in Life Sci­ence Inno­va­tions a spe­cial­ist VC fund based in Poland and a direc­tor or men­tor to a num­ber of start-​up companies.


Katarzyna Koziak

Dr. Katarzyna Koziak is a grad­u­ate cum laude from the Depart­ment of Embry­ol­ogy at the Fac­ulty of Biol­ogy of Uni­ver­sity of War­saw. Already as a stu­dent of Prof. Andrzej Tarkowski she joined the research team of Jacques Tes­tart and Rene Fry­d­man in Paris, France, where she worked on gametes mat­u­ra­tion and clin­i­cal aspects of in vitro fer­til­iza­tion. After her return to Poland, dr. Koziak started to work at the Med­ical Uni­ver­sity of War­saw where she in 1994 obtained her Ph.D. cum laude pre­sent­ing a dis­ser­ta­tion on ery­thro­poi­etin pro­duc­tion in kid­ney trans­plant recip­i­ents. Her sci­en­tific career con­tin­ued in the United States, where she moved for a five-​year post­doc­toral train­ing at Har­vard Med­ical School. Work­ing in Sandoz-​founded Fritz Bach’s group dr. Koziak inves­ti­gated endothe­lial cell biol­ogy and was one of the dis­cov­er­ers of NTP­Dase I, the key endothe­lial enzyme reg­u­lat­ing vas­cu­lar coag­u­la­tion and home­osta­sis. Fol­low­ing her return to Poland, she con­tin­ued research on vas­cu­lar inflam­ma­tion and in 2006 defended cum laude a habil­i­ta­tion (D.Sc.) dis­ser­ta­tion. As an rec­og­nized and expe­ri­enced researcher dr. Koziak par­tic­i­pates as a prin­ci­pal inves­ti­ga­tor or co-​investigator in sev­eral research projects in fields of vas­cu­lar biol­ogy founded mostly by Pol­ish Com­mit­tee for Sci­en­tific Research, Euro­pean Coun­cil, Pol­ish National Sci­ence Cen­ter and Foun­da­tion of Pol­ish Sci­ence. Dr. Katarzyna Koziak co-​authored numer­ous research arti­cles, text books and patent appli­ca­tions. She is also a rec­og­nized aca­d­e­mic teacher, cur­rently respon­si­ble for spe­cial­ized cur­ricu­lum in bio­chem­istry for stu­dents of Med­ical Uni­ver­sity of War­saw. Dr. Koziak’s achieve­ments were rec­og­nized by Pol­ish author­i­ties – she received twice the award of Prime Min­is­ter of Poland.


Mateusz Kowalewski

Part­ner Augere Health Food Fund, investor, indus­try expert. Fam­ily entre­pre­neur in the sec­ond gen­er­a­tion. Co-​owner and CEO of HOR­TIMEX. Since 2009 he man­ages a com­pany, a plat­form for the exchange of goods, knowl­edge and expe­ri­ence between global food ingre­di­ents pro­duc­ers and Pol­ish food pro­duc­ers. Prac­tices of mod­ern orga­ni­za­tion and man­age­ment of fam­ily business.


Olga Krylova

Olga Krylova, PhD, Senior Direc­tor, UK Global Scout, Exter­nal R&D Inno­va­tions, Pfizer

Olga holds PhD in Neu­ro­bi­ol­ogy from Russ­ian Acad­emy of Med­ical Sciences.

From 2006 she worked for Mit­sui & Co Europe, Lon­don, as Senior Researcher in Busi­ness Devel­op­ment sup­port­ing pri­vate equity invest­ment and pharma-​related business.

Prior to that she worked as a Prin­ci­ple Sci­en­tist in Glax­o­SmithK­line R&D, Psy­chi­a­try Cen­tre of Excel­lence for Drug Dis­cov­ery in the UK. In her role at GSK Olga led pro­grams in early dis­cov­ery research for schiz­o­phre­nia and Bipo­lar Disorder.

Olga moved to the UK in 1994 to do a post-​doctoral study in UCL fol­lowed a sim­i­lar posi­tion in Impe­r­ial College.

At her cur­rent role in Pfizer Olga is head­ing Pfizer R&D Scout­ing efforts in the UK look­ing for oppor­tu­ni­ties to part­ner from aca­d­e­mic research to POC clin­i­cal stage assets across all the ther­a­peu­tic areas of Pfizer inter­est which are CVMet, Inflammation&Immunology, Neu­ro­science, Oncol­ogy, Rare Dis­ease and Vaccines.

dr Gabor Lamm

Gabor Lamm

Dr. Lamm (born 1967 in Budapest) is a grad­u­ate of Edin­burgh Uni­ver­sity (Bio­chem­istry) and holds a Ph.D. in Mol­e­c­u­lar Biol­ogy. After spend­ing three years as a research sci­en­tist at the Boehringer Ingel­heim Insti­tute of Mol­e­c­u­lar Pathol­ogy (IMP) in Vienna, Dr. Lamm joined Wacker Chemie, a major global sup­plier of sil­i­cone and poly­mer raw mate­ri­als and semi­con­duc­tors. At Wacker Chemie Dr. Lamm was Business-​Team Leader in the divi­sion spe­cial­is­ing in advanced ceramic com­po­nents for high-​tech appli­ca­tions. As of Octo­ber 2000 he is Man­ag­ing Direc­tor of EMBL Enter­prise Man­age­ment Tech­nol­ogy Trans­fer GmbH (EMBLEM), a 100% sub­sidiary of the Euro­pean Mol­e­c­u­lar Biol­ogy Lab­o­ra­tory (EMBL; http://​www​.embl​.org). Dr. Lamm is an alum­nus of the Euro­pean Mol­e­c­u­lar Biol­ogy Lab­o­ra­tory Ph.D. pro­gram and of the Boehringer Ingel­heim Fonds, on the advi­sory board of var­i­ous asso­ci­a­tions and start-​up com­pa­nies, co-​founder of the VC vehi­cle EMBL-​Ventures, and for­mer vice-​president (20022006) of the Asso­ci­a­tion of Euro­pean Sci­ence and Tech­nol­ogy Trans­fer Pro­fes­sion­als (ASTP).

Magdalena Marciniak

Mag­dalena Marciniak

Mag­dalena holds a MSc degree in Food Sci­ence and Human Nutri­tion from the Uni­ver­sity of Agri­cul­ture in Krakow and BSc in Man­age­ment from the same Uni­ver­sity. In years 20102011 she had an intern­ship at Uni­ver­sity of Copen­hagen at Life Sci­ence Depart­ment, where she was involved in sev­eral sci­en­tific and inter­dis­ci­pli­nary projects.

Based on her pre­vi­ous expe­ri­ence Mag­dalena is a qual­i­fied man­ager with strong back­ground in the area of FMCG, retail mar­ket and pro­duc­tion. Mag­dalena joined Selvita in 2015, tak­ing the posi­tion of Busi­ness Alliance Man­ager in the R&D Depart­ment, com­bin­ing sci­en­tific back­ground with exces­sive busi­ness man­age­ment skills. Mag­dalena was involved in nego­ti­at­ing and man­ag­ing part­ner­ing deals with H3 Bio­med­i­cine, Merck KGaA and Nodthera. She is also respon­si­ble for in-​licensing dis­cus­sion with pharma/​biotech com­pa­nies and investors.


Ste­fan Ogrodzinski

Ste­fan Ogrodzin­ski received his BSc (Hons) in Tox­i­col­ogy and Phar­ma­col­ogy from The School of Phar­macy, Uni­ver­sity Col­lege Lon­don, in 1987 and his MBA from De Mont­fort Uni­ver­sity in 1999. Stefan’s career has spanned the phar­ma­ceu­ti­cal indus­try, the health­care sec­tor, the vol­un­tary sec­tor and the edu­ca­tional sec­tor, giv­ing 25 years of sales, mar­ket­ing, man­age­ment and direc­tor­ship expe­ri­ence. In 2000, Ste­fan founded BioSta­tus and has led the com­pany as its CEO. As a found­ing Direc­tor of BioSta­tus, Ste­fan is respon­si­ble for the over­all direc­tion and strate­gic man­age­ment of the busi­ness. Ste­fan is also a Direc­tor of Bio­Sus­pen­sions, OncoTher­ics, BioC­ity, MediC­ity and Mobius. He sits on the advi­sory panel for the Cen­tre for Doc­toral Train­ing in Tar­geted Ther­a­peu­tics and For­mu­la­tion Sci­ence at Not­ting­ham Uni­ver­sity and serves as a UKTI Cat­a­lyst Ambassador.


Jarosław Oleszczuk

His pro­fes­sional expe­ri­ence includes 3 years of med­ical prac­tice, 5 years of con­sult­ing career at McK­in­sey & Com­pany in War­saw and Chicago and 10 years of man­age­ment in inter­na­tional phar­ma­ceu­ti­cal cor­po­ra­tions (Novar­tis, Abbott Lab­o­ra­to­ries and Abb­Vie). From Octo­ber 2009 till to Decem­ber 2012 he was the C of the Man­age­ment Board of Abbott Lab­o­ra­to­ries Poland Sp. o. o. where, among other things, he devel­oped and imple­mented Solvay Phar­ma­ceu­ti­cals busi­ness inte­gra­tion strate­gies with his par­ent com­pany. At that time he was also a mem­ber of the INFARMA Super­vi­sory Board. From Jan­u­ary 2013 to Octo­ber 2014 he was Pres­i­dent of the Board of Abb­Vie Pol­ska — he was the founder of Abb­Vie Pol­ska, which was formed from the spin-​off of the phar­ma­ceu­ti­cal busi­ness with Abbott Lab­o­ra­to­ries. Between Octo­ber 2014 and May 2016 Abb­Vie was Chair­man of the Board of Direc­tors of Bel­gium and Lux­em­bourg. He is the author or co-​author of more than 100 pub­li­ca­tions in the world’s sci­en­tific jour­nals. He com­pleted his med­ical stud­ies at the Med­ical Uni­ver­sity of Lublin and his doc­tor­ate at the Insti­tute of Mother’s Health in Łódź, win­ning the Prime Minister’s Award.

In the years 20102014 he was asso­ci­ated with INFARMA, first as a mem­ber of the Super­vi­sory Board, then as a mem­ber of the Board and a Trea­surer. In the years 20142016 he was also a mem­ber of the board of PHARMA​.BE — Bel­gian and Lux­em­bourg phar­ma­ceu­ti­cal and biotech asso­ci­a­tions, com­pris­ing more than 130 mem­ber companies.


Mar­tin Oxley

Mar­tin Oxley has spent his career in a fast mov­ing emerg­ing mar­kets with a focus on busi­ness strat­egy & devel­op­ment. He has held top man­age­ment posi­tions in a num­ber of Blue Chip & CEE based phar­ma­ceu­ti­cal com­pa­nies. He has also been a CEO of the British Pol­ish Cham­ber of Com­merce (BPCC), which under his lead­er­ship was rec­og­nized as the Best British Cham­ber of Com­merce in Europe for four con­sec­u­tive years. He was Direc­tor Gen­eral of UK Trade & Invest­ment at the British Embassy in War­saw, where he led on the deliv­ery of the British government’s world renowned GREAT cam­paign in Cen­tral Europe, one of the best ever coun­try pro­mo­tion cam­paigns. Mar­tin has worked with most of the lead­ing UK based inter­na­tional cor­po­ra­tions as they have devel­oped in the CEE region. In addi­tion to his role as Inter­na­tional Direc­tor IORMA, Mar­tin is Chair­man of Exorigo-​Upos Group and holds a num­ber of Advi­sory Board posi­tions with inno­v­a­tive star­tups. He is pas­sion­ate about dig­i­tal innovation.


George Rahim

George is a phar­ma­ceu­ti­cal part­ner­ing exec­u­tive with sev­en­teen years’ expe­ri­ence in Global Busi­ness Devel­op­ment and Alliance Man­age­ment at Roche and Glax­o­SmithK­line Bio­log­i­cals and prior to that, broad inter­na­tional expe­ri­ence in Med­i­c­i­nal Chem­istry and R&D, Project and Line Man­age­ment and Busi­ness Con­sult­ing in Biotechnology.

George recently joined UCB to help estab­lish the Alliance Man­age­ment Cen­tre of Exper­tise and cre­ate patient value from exter­nal part­ner­ships and is cur­rently devel­op­ing an Alliance Man­age­ment Com­mu­nity of Prac­tice within UCB. Before join­ing UCB, George was the Head of Alliance Man­age­ment and Oper­a­tions at Glax­o­SmithK­line Bio­log­i­cals in Bel­gium. George’s pro­fes­sional expe­ri­ence spans the entire phar­ma­ceu­ti­cal value chain from dis­cov­ery to com­mer­cial­iza­tion related to small mol­e­cules, bio­log­i­cals and vac­cines and he is a rec­og­nized prac­ti­tioner in alliance man­age­ment with both cor­po­rate and aca­d­e­mic partners.

George holds a PhD in Chem­istry from the Uni­ver­sity of Birm­ing­ham, UK.


Radosław Rudź

Radosław Rudź, PhD. in Med­ical Biol­ogy also with edu­ca­tion back­ground in Man­age­ment and Pro­tec­tion of Envi­ron­ment. Cur­rently works in Cen­tre for Tech­nol­ogy Trans­fer CIT­TRU (Jagiel­lon­ian Uni­ver­sity in Krakow) as Head of Tech­nol­ogy Trans­fer and Coop­er­a­tion with Econ­omy Team. Apart from man­age­ment of the Team his main duties cover com­mer­cial­iza­tion of life sci­ence inven­tions from Jagiel­lon­ian Uni­ver­sity, includ­ing drug devel­op­ment projects. He nego­ti­ated suc­cess­fully sev­eral med­i­cine and pharma projects which were com­mer­cial­ized in coop­er­a­tion with Pol­ish and for­eign com­pa­nies. He has also expe­ri­ence in Health Tech­nol­ogy Assess­ment area includ­ing cre­ation and audit­ing of phar­ma­coeco­nomic reports filed to Agency for Health Tech­nol­ogy Assess­ment in Poland for pub­lic reim­burse­ment of drugs.


Marcin Szu­mowski

Marcin Szu­mowski is ser­ial entre­pre­neur. He received his MS and PhD degrees from the Uni­ver­sity of Illi­nois and earned an MBA degree in entre­pre­neur­ship and inter­na­tional finance. Fol­low­ing a suc­cess­ful research career in the United States, Marcin has been involved in tech­nol­ogy trans­fer and start-​up com­pa­nies since 2000 and has co-​founded and man­aged five start-​ups, includ­ing a med­ical diag­nos­tics com­pany Med­ical­go­rith­mics S.A. (www​.med​ical​go​rith​mics​.com), where he was Pres­i­dent and CEO 20052010. Med­ical­go­rith­mics is now traded on the War­saw Stock Exchange with a mar­ket cap over $300M and global sales. Since 2012 he is Pres­i­dent & CEO of OncoArendi Ther­a­peu­tics S.A. (www​.oncoarendi​.com), a Pol­ish inno­v­a­tive bio­phar­ma­ceu­ti­cal com­pany ded­i­cated to devel­op­ing and com­mer­cial­iz­ing novel ther­a­peu­tics for neo­plas­tic and inflam­ma­tory dis­eases. In four years the com­pany has grown to almost 70 employ­ees and over $35M research fund­ing from pri­vate investors and pub­lic grants. Marcin is also one of co-​founders and lead investors in the Life Sci­ence Inno­va­tions (LSI) early stage fund. Since 2012 Marcin has also assisted the Euro­pean Com­mis­sion on three inde­pen­dent expert pan­els per­form­ing the impact assess­ment, interim and final eval­u­a­tions of the Inno­v­a­tive Med­i­cines Ini­tia­tive (IMI), the world’s largest public-​private part­ner­ship (PPP) in phar­ma­ceu­ti­cal research. Over the last 15 years Marcin has man­aged over 40 R&D and invest­ment projects with a total value well over $250M.


Irina Staatz-​Granzer

Irina Staatz-​Granzer, PhD, founder and owner of Staatz Busi­ness Devel­op­ment & Strat­egy has more than 20 years of busi­ness devel­op­ment expe­ri­ence in the phar­ma­ceu­ti­cal and biotech­nol­ogy indus­try. She has suc­cess­fully nego­ti­ated a broad vari­ety of global, regional and local agree­ments with an aggre­gate deal value exceed­ing USD 1.7 BN. She and her team advise and sup­port lead­ing VC firms as well as inter­na­tional biotech and phar­ma­ceu­ti­cal com­pa­nies in the strat­egy and the oper­a­tions of their tech­nol­ogy /​project /​prod­uct licens­ing, col­lab­o­ra­tions and divestment/​acquisitions includ­ing M&A on the sell as well as on the buy side. Prior to her own busi­ness she held var­i­ous indus­trial C level posi­tions (includ­ing CEO/​VP) at Her­mal (Merck KGaA), Boots Health­care Intl, Knoll (later Abbott), Scil Tech­nol­ogy, U3 Pharma, Blink Bio­med­ical. She is Vice Chair­man of the pub­lic Innate Pharma and Chair­man of pri­vate BliNK Bio­med­ical, both France, and Found­ing Mem­ber and Pres­i­dent of the Ger­man Pharma Licens­ing Club.


Mark Tre­herne

Mark has been actively involved in the bio­phar­ma­ceu­ti­cal indus­try for 25 years and was a co-​founder in 1997 and Chief Exec­u­tive of Cam­bridge Drug Dis­cov­ery, lead­ing the Company’s acqui­si­tion by Bio­Fo­cus plc, where he then became a Com­mer­cial Direc­tor, dri­ving sig­nif­i­cant growth of its prof­itable ser­vices busi­ness. Mark has now served on the Boards of 15 pri­vate and pub­lic bio­phar­ma­ceu­ti­cal com­pa­nies in Aus­tralia, France, Den­mark, the Nether­lands and the UK. Mark joined the Life Sci­ences Organ­i­sa­tion (LSO) as Chief Exec­u­tive in 2012, fol­low­ing its for­ma­tion by‎ UK Trade & Invest­ment‎. While at the LSO he worked with the UK Gov­ern­ment to bring in £6 bil­lion in inward invest­ment, before leav­ing to return to the biotech­nol­ogy sec­tor in 2016. Mark is cur­rently Chief Exec­u­tive of Avilex Pharma in Copen­hagen. He ini­tially trained as a neu­ro­sci­en­tist and elec­tro­phys­i­ol­o­gist at Cam­bridge Uni­ver­sity in the 1980s.‎


Woj­ciech Tworzyński

Mr Tworzyn­ski is respon­si­ble for project analy­sis and deeply involved in the process of solic­it­ing projects and main­tain­ing rela­tion­ships with the sci­en­tific and start-​up envi­ron­ment in Poland. Before JPIF, he worked for a highly spe­cial­ized med­ical device com­pany where he was prod­uct man­ager and advi­sor for clin­i­cal stud­ies. Mr Tworzyn­ski holds a degree in mol­e­c­u­lar biol­ogy (genet­ics and biotech­nol­ogy) from War­saw University.


Simon Wall­work

With over 28 years expe­ri­ence advis­ing on acqui­si­tions, dis­pos­als, pri­vate equity and pub­lic mar­ket trans­ac­tions, for a wide vari­ety of clients includ­ing pub­lic and pri­vate com­pa­nies, banks, ven­ture cap­i­tal funds and part­ner­ships, Simon also has con­sid­er­able client side expe­ri­ence spend­ing a num­ber of years work­ing in-​house with Pilk­ing­ton plc where he was involved in a num­ber of cross bor­der transactions.

Simon has worked in the life sci­ences sec­tor for over 20 years hav­ing acted on the list­ing of Oxford Mol­e­c­u­lar Group plc. He has acted for many com­pa­nies in the sec­tor from incor­po­ra­tion through fund­ing rounds to even­tual exit by way of sale or IPO. He has a deep under­stand­ing of the sec­tor and its key drivers.


  • media_wrzesien17
  • newsletter_lipiec
  • newsletter_luty_2017_a
  • newsletter_maj_d


Under con­struc­tion



Life Sci­ence Biznes Con­sult­ing LSBC Sp. z o. o. allows a change of reg­is­trant at no extra cost if the orig­i­nal reg­is­trant is unable to attend.

In the event of can­cel­la­tion of the Con­fer­ence by the orga­niz­ers all fees paid by del­e­gates will be returned in full although Life Sci­ence Biznes Con­sult­ing LSBC Sp. z o. o. is not respon­si­ble for any other finan­cial losses such as travel and hotel costs.

In the event that a del­e­gate or accom­pa­ny­ing per­son can­cels atten­dance at the con­fer­ence Life Sci­ence Biznes Con­sult­ing LSBC Sp. z o. o. will return 60% of the reg­is­tra­tion fee if atten­dance is can­celled before Fri­day 18 Sep­tem­ber 2015. There­after there will be no return of fees.

Life Sci­ence Biznes Con­sult­ing LSBC Sp. z o. o. is not liable in any way for any injuries, sick­ness or acci­dent or any costs incurred as a con­se­quence of such an event or any other losses to which a del­e­gate or accom­pa­ny­ing per­son may be sub­jected to whist trav­el­ling to or from Poland or whilst attend­ing the con­fer­ence in Krakow or any of the social events organized.

The speak­ers listed have all con­firmed their atten­dance and have agreed to post their pho­tographs on this web­site. How­ever Life Sci­ence Biznes Con­sult­ing LSBC Sp. z o. o. informs del­e­gates and speak­ers that that the final agenda could change for rea­sons beyond its con­trol. Life Sci­ence Biznes Con­sult­ing LSBC Sp. z o. o. reserves the right to make changes to the agenda and is not respon­si­ble for any finan­cial losses or costs incurred by par­tic­i­pants or del­e­gates in asso­ci­a­tion with their par­tic­i­pa­tion at this conference.



selvitalogo selvitalogo wts wts




malopolska centre of biotechnology logo Oncoarendi

media part­ner

biotechnologia dolina bio technologiczna pl logo
European Biotechnology Network


Under con­struc­tion


Under con­struc­tion